Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED	
ABN	42 616 305 027	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bronwyn LE GRICE
Date of last notice	4 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct (as joint holder with Tom James Le Grice as trustees for Leftie Group Australia Discretionary Trust)	
Nature of indirect interest	N/A	
(including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		
Date of change	6 June 2018	
No. of securities held prior to change	Nil	
Class	Performance rights each will automatically vest into one Share on the vesting date of 26 April 2020 (Performance Rights).	
Number acquired	150,000 Performance Rights	
Number disposed	N/A	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A	
No. of securities held after change	150,000 Performance Rights each will automatically vest into one Share on the vesting date of 26 April 2020.	

⁺ See chapter 19 for defined terms.

Nature of change	Issue of Performance Rights pursuant to the
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Company's LTIP, as approved by shareholders on 31 May 2018.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

N/A	
N/A	
	N/A N/A N/A N/A N/A N/A N/A N/A N/A

Were the interests in the securities or contracts detailed above traded	No
during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED	
ABN	42 616 305 027	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David LUDVIGSON
Date of last notice	4 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 June 2018
No. of securities held prior to change	150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one fully paid ordinary share (Share) on the vesting date of 22 June 2019.
Class	Performance rights each will automatically vest into one Share on the vesting date of 6 June 2020 (Performance Rights)
Number acquired	50,000 Performance Rights
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

⁺ See chapter 19 for defined terms.

No. of securities held after change	 150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one Share on the vesting date of 22 June 2019. 50,000 Performance Rights each will automatically vest into one Share on the vesting date of 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights pursuant to the Company's LTIP, as approved by shareholders on 31 May 2018.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

N/A
N/A
_

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED	
ABN	42 616 305 027	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jovanka NAUMOSKA
Date of last notice	4 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 June 2018
No. of securities held prior to change	150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one fully paid ordinary share (Share) on the vesting date of 22 June 2019.
Class	Performance rights each will automatically vest into one Share on the vesting date of 6 June 2020 (Performance Rights)
Number acquired	50,000 Performance Rights
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

⁺ See chapter 19 for defined terms.

No. of securities held after change	 150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one Share on the vesting date of 22 June 2019. 50,000 Performance Rights each will automatically vest into one Share on the vesting date of 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights pursuant to the Company's LTIP, as approved by shareholders on 31 May 2018.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

N/A
N/A
_

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED	
ABN	42 616 305 027	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark VAN ASTEN
Date of last notice	4 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 June 2018
No. of securities held prior to change	150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one fully paid ordinary share (Share) on the vesting date of 22 June 2019.
Class	Performance rights each will automatically vest into one Share on the vesting date of 6 June 2020 (Performance Rights)
Number acquired	50,000 Performance Rights
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A

⁺ See chapter 19 for defined terms.

No. of securities held after change	 150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one Share on the vesting date of 22 June 2019. 50,000 Performance Rights each will automatically vest into one Share on the vesting date of 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights pursuant to the Company's LTIP, as approved by shareholders on 31 May 2018.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A
Interest after change	N/A

Were the interests in the securities or contracts detailed above traded	No
during a ⁺ closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period? If prior written clearance was provided, on what date was this	N/A
provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	IMAGION BIOSYSTEMS LIMITED	
ABN	42 616 305 027	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael HARSH
Date of last notice	4 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A	
Date of change	6 June 2018	
No. of securities held prior to change	150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one fully paid ordinary share (Share) on the vesting date of 22 June 2019.	
Class	Performance rights each will automatically vest into one Share on the vesting date of 6 June 2020 (Performance Rights)	
Number acquired	50,000 Performance Rights	
Number disposed	N/A	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A	

⁺ See chapter 19 for defined terms.

No. of securities held after change	 150,000 performance rights, escrowed for 24 months from official quotation, issued under the Company's LTIP, and will each vest into one Share on the vesting date of 22 June 2019. 50,000 Performance Rights each will automatically vest into one Share on the vesting date of 6 June 2020.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights pursuant to the Company's LTIP, as approved by shareholders on 31 May 2018.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A
interest after change	IN/A

Were the interests in the securities or contracts detailed above traded	No
during a ⁺ closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.